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Summary 
We have used a combination of genetics and pharma- 
cology to assess the effects of reduced DNA methyl- 
transferase activity on ApcM~"-induced intestinal neopla- 
sia in mice. A reduction in the DNA methyltransferase 
activity in Min mice due to heterozygosity of the DNA 
methyltransferase gene, in conjunction with a weekly 
dose of the DNA methyltransferase inhibitor 5-aza- 
deoxycytidine, reduced the average number of intesti- 
nal adenomas from 113 in the control mice to only 2 
polyps in the treated heterozygotes. Hence, DNA methyl- 
transferase activity contributes substantially to tumor 
development in this mouse model of intestinal neopla- 
sia. Our results argue against an oncogenic effect of 
DNA hypomethylation. Moreover, they are consistent 
with a role for ONA methyltransferase in the generation 
of the C to T transitions seen at high frequency in hu- 
man colorectal tumors. 
Introduction 
Methylation of mammalian DNA is found as the covalent 
modification of the fifth carbon position of the pyrimidine 
ring of cytosines in CpG dinucleotides (Adams and Bur- 
don, 1982; Gardiner-Garden and Frommer, 1987; Ante- 
quera and Bird, 1993). Newly replicated DNA lacks this 
methylation in the nascent strand. Shortly after passage 
of the replication fork, a maintenance DNA methyltransfer- 
ase methylates CpG dinucleotides on the newly synthe- 
sized strand at sites opposite to those methylated in the 
parental strand, thereby recreating the spectrum of methyl 
groups that existed prior to replication. So far, only one 
mammalian DNA (cytosine-5) methyltransferase nzyme 
(EC 2.1.1.37) has been identified and characterized (Bes- 
tor et al., 1988; Leonhardt and Bestor, 1993). The carboxy- 
terminal part of this protein shares sequence similarity 
with the conserved catalytic domain of prokaryotic DNA 
(cytosine-5) methyltransferases (Lauster et al., 1989; Pos- 
fai et al., 1989; Kumar et al., 1994). The mammalian en- 
zyme has an additional large amino-terminal extension 
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lacking sequence similarity to other known DNA methyl- 
transferases. This amino-terminal region is thought to be 
a regulatory domain and is known to contain signals neces- 
sary for the targeted localization of the enzyme to replica- 
tion foci in the nucleus (Leonhardt et al., 1992). 
Changes in the pattern of DNA methylation have been 
correlated with a number of different processes in mam- 
mals. These include the expression level of genes (Yeivin 
and Razin, 1993), chromatin structure (Keshet et al., 1986; 
Tazi and Bird, 1990; Kass et al., 1993), the timing of DNA 
replication (Selig et al., 1988), genomic imprinting (Barlow, 
1993; Li et al., 1993), and somatic X-chromosomal inacti- 
vation in females (Monk and Grant, 1990; Singer-Sam and 
Riggs, 1993). Whether DNA methylation is a cause or a 
consequence of these processes remains in large part to 
be resolved. Nevertheless, it is clear that DNA methylation 
is an essential process in mammalian development, since 
mouse embryos deficient for the known DNA methyltrans- 
ferase do not survive past mid gestation (Li et al., 1992). 
Several observations implicate a role for DNA methyla- 
tion in cancer pathogenesis. Changes in the pattern of 
DNA methylation are commonly seen in human tumors 
(Jones and Buckley, 1990; Baylin et al., 1991; Spruck et 
al., 1993; Laird and Jaenisch, 1994). Some loci tend to 
show increased levels of DNA methylation (Ohtani-Fujita 
et al., 1993; Issa et al., 1994), whereas others are often 
hypomethylated (Feinberg and Vogelstein, 1983a, 1983b; 
Goelz et al., 1985; Rao et al., 1989; Vorce and Goodman, 
1991 ; Hanada et al., 1993). The global level of DNA methyl- 
ation is generally lower in tumor cells than in normal cells 
(Gama-Sosa et al., 1983; Feinberg et al., 1988). This de- 
crease in the overall evel of DNA methylation is curious in 
light of the normal to high levels of DNA methyltransferase 
expression usually seen in tumor cells (Kautiainen and 
Jones, 1986; EI-Deiry et al., 1991; Issa et al., 1993). 
Some investigators have proposed that changes in DNA 
methylation contribute to oncogenesis by affecting the ex- 
pression levels of proto-oncogenes and tumor-suppressor 
genes. Thus, DNA hypomethylation would allow increased 
expression of oncogenes; alternatively, DNA hypermethy- 
lation would help to silence tumor-suppressor genes. How- 
ever, there is no direct evidence that either mechanism 
is operative in oncogenesis. Indeed, it is not even clear 
whether the changes in DNA methylation play a causal 
role in oncogenesis or whether they are merely a conse- 
quence of the transformed state of the tumor cell. 
We have designed experiments in an attempt o distin- 
guish between these alternatives. Using a combination 
of genetics and pharmacology, we have manipulated the 
levels of functional DNA methyltransferase in mice and 
determined the consequences for early steps of the neo- 
plastic process. To do so, we used mice heterozygous 
for the multiple intestinal neoplasia (Min) mutation of the 
adenomatosis polyposis coil (Apc) gene (Min mice) as a 
model system to assess the role of DNA methylation in 
early neoplastic transformation (Moser et al., 1990; Suet 
al., 1992; Luongo et al., 1993, 1994). Min mice develop 
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multiple intestinal adenomas within the first few months 
of life (Moser et al., 1990, 1992; Luongo et al., 1994). The 
number of intestinal polyps present in these mice at spe- 
cific ages offered us a readily quantifiable measure of any 
effects that changes in DNA methylation might have on 
the incidence or rate of polyp formation. 
Min mice carry a germline point mutation in the Apc,  
tumor-suppressor gene, the mouse homolog of the human 
APC gene, which, when present in mutant form in the hu- 
man germ line, results in the syndrome of familial adeno- 
matous polyposis coli (FAP; Su et aL, 1992). FAP patients 
develop as many as 1000 benign colorectal polyps, some 
of which progress to malignancy if they are not removed 
(Groden et al., 1991; Joslyn et al., 1991; Ichii et al., 1992; 
Miyoshi et al., 1992; Powell et al., 1992; Nakamura, 1993). 
Similarly, mice carrying the Min allele of the Apc gene 
develop 100 or more intestinal polyps in the first 6 months 
of life. These polyps thus provide a model system for the 
early stages of human colorectal cancer, for which changes 
in DNA methylation patterns and in methyltransferase ex- 
pression have been well documented (GamaoSosa et al., 
1983; Feinberg et al., 1988; Silverman et al., 1989; EI-Deiry 
et al., 1991; Issa et al., 1993). 
We have previously generated mice carrying germline 
mutations in the DNA methyltransferase gene (Dnmt; Li 
et al., 1992, 1993). Mouse embryos homozygous for either 
the Dnmt v allele (Li et al., 1992) or the stronger Dnmt s 
allele (Li et al., 1993) die before birth. Heterozygous mice 
have approximately half wild-type levels of DNA methyl- 
transferase expression, which is apparently sufficient to 
maintain normal levels of DNA methylation (Li et al., 1992). 
They appear otherwise phenotypically indistinguishable 
from their wild-type littermates. 
In the present study, we further perturbed methyltrans- 
ferase activity through use of the DNA methyltransferase 
inhibitor 5-aza-2'-deoxycytidine (5-aza-dC), which is known 
to titrate out the enzyme activity by a covalent trapping 
mechanism (Santi et al., 1983, 1984; J0ttermann et al., 
1994). The combination of Dnmt heterozygosity and treat- 
ment with 5-aza-dC might be predicted to reduce the func- 
tional levels of DNA methyltransferase tobelow the thresh- 
old needed for maintenance of normal DNA methylation 
patterns. In this paper, we employ this combined strategy 
to study the effects of reduced DNA methyltransferase 
activity and consequent DNA methylation levels on the 
number of intestinal adenomas appearing in mice carrying 
the Min allele of the Apc gene. 
Results 
Effects of Decreased DNA Methyltransferase 
Activity on the Number of Intestinal Adenomas 
To study the effects of DNA methyltransferase levels on 
intestinal polyp formation, we crossed 129/Sv Dnmt ~÷ fe- 
male mice with C57BL/6 Apc MinI+ males. In addition, we 
determined the maximal dose of 5-aza-dC that mice could 
tolerate during an extended treatment protocol starting at 
1 week of age. This dose (5 p+g of 5-aza-dC per 5 grams 
body weight) was given weekly by subcutaneous injection 
to the progeny of the cross described above. Control off- 
spring were injected with phosphate-buffered saline (PBS) 
instead of 5-aza-dC. The injections were performed by 
investigators blind to the genotypes of the animals. 
Previous experience indicated that at 100 days of age, 
a subset of intestinal polyps are just at the threshold of 
detectability in this strain background. During the subse- 
quent 80 days, such polyps grow to a size that is readily 
visible. For this reason, mice were injected with either 
5-aza-dC or PBS for 100 days (14 injections). The drug 
treatment was then discontinued, and the number of pol- 
yps was monitored 80 days later, allowing us to gauge the 
effects of DNA methyltransferase l vels on polyp initiation 
and early growth during the first 100 days of life. In doing 
so, we avoided any cytotoxic or cytostatic effects that 
5-aza-dC might have on the expansion of cell populations 
in the polyps during the growth period from 100 to 180 
days. Figure 1 shows growth curves for the four different 
genotypes generated in this cross. As is apparent, the 
treatment with 5-aza-dC did not have a significant effect 
on the body weights of the mice. 
A parallel cohort of animals was sacrificed at 100 days 
to determine the DNA methylation levels in the colon im- 
mediately following 5-aza-dC treatment. Figure 2 shows 
an analysis of DNA methylation levels of genomic colonic 
DNA derived from the Dnmt heterozygous and wild-type 
animals treated with or without 5-aza-dC. We compared 
DNA methylation levels by Southern blot analysis of re- 
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Figure 1. Growth Curves of Mice Treated Weekly with either PBS or 
5-aza-dC 
129/Sv Dnmt ~* female mice were crossed to C57BL/6 Apc Mw+ males. 
Ungenotyped progeny were weighed and injected weekly with either 
5 pg of 5-aza-dC per 5 g of bodyweight or with its solvent, PBS. The 
injections were continued for 100 days (14 injections), after which the 
mice were monitored for an additional 80 days and then sacrificed. 
The average weights were calculated for each of the genotypes, exes, 
and treatments. The weight measurements were plotted by week. How- 
ever, the symbols are indicated only every 5 weeks to preserve clarity. 
Squares, males; circles, females; open symbols, PBS treatment; 
closed symbols, 5-aza-dC treatment. (A) Dnmt +1*, Apc ÷/÷ mice; (B) 
Dnmt *t*, Apc Mhw mice; (C) Dnmt "~, Apc *]+ mice; (D) Dnmt ~+, Apc ujn]* 
mice. 
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Figure 2. DNA Methylation Analysis of Genomic Colonic DNA from 
Mice Treated Weekly with orwithout 5-aza-dC 
Mice derived from a cross between 129/Sv DnmP ~* females and a 
C57BL/6 male were injected weekly with 5-aza-dC for 100 days (14 
weeks) or untreated. Genomic DNA from colons collected from 100- 
day-old mice was isolated asdescribed previously (Laird et al., 1991). 
Analysis of DNA methylation levels involved igestion of genomic DNA 
by the methylation-sensitive restriction enzyme Hpall, followed by hy- 
bridization with a centromeric minor satellite repeat probe (Chapman 
et al., 1984) for a reflection of the global DNA methylation status. The 
Dnmt genotypes and treatments are indicated above the lan s. 
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Figure 3. The Number of Intestinal Polyps in Mice Treated Weekly 
with either PBS or 5-aza-dC 
129/Sv Dnmt u+ female mice were crossed to C57BL/6 Apc A~v+ males. 
Ungenotyped progeny were weighed and injected weekly with either 
5 p.g of 5-aza-dC per 5 g of bodyweight or with its solvent, PBS. The 
injections were continued for 100 days (14 injections), after which the 
mice were monitored for an additional 80 days and then sacrificed. 
The entire intestine was excised immediately following sacrifice, fixed 
and washed with Bouin's fixative, and subjected to a systematic micro- 
scopic screen for polyp formation along the entire length of the intes- 
tine. The investigator counting the polyps was blind tobeth Apc and 
Dnmt genotypes. The average number of polyps for each group is 
shown as a bar with the average also indicated above or within the 
bar; SEM is indicated by the thin error bars. The treatments, genotypes 
of the mice, and number of mice ineach experimental group are indi- 
cated below the bars. All mice for this experiment were generated by 
the same limited number of parents and were maintained in the same 
room with the same food and cage conditions. 
striction digests with the DNA methylation-sensitive en- 
zyme Hpall, hybridized with a centromeric minor satellite 
repeat probe (Chapman et al., 1984) (see Figure 2). In this 
assay, reduced levels of DNA methylation are revealed 
by a relative increase in lower molecular weight bands. 
The analysis in Figure 2 shows that both Dnmt heterozy- 
gosity and 5-aza-dC treatment have a synergistically hypo- 
methylating effect on colonic DNA. The effect of 5-aza-dC 
appears to be stronger than that of Dnmt heterozygosity. 
The number of intestinal polyps at sacrifice at 180 days 
was determined by examination of the mucosa over the 
entire length of the intestine under a dissecting micro- 
scope. Figure 3 shows the averaged results obtained for 
the various experimental groups. Mice wild-type at the Apc 
locus did not develop intestinal polyps with any combina- 
tion of Dnmtgenotype or drug treatment. Ape "Mi~ heterozy- 
gous mice developed an average of 113 polyps in the 
Dnmt */÷ PBS control group. Dnmt s heterozygosity reduced 
the number to a statistically significant lower average of 
only 46 polyps (p ~< 0.001 in Student's t test). A more pro- 
nounced effect was seen in theApc Mj"~+ heterozygous mice 
treated with 5-aza-dC. Treatment of Dnmt wild-type mice 
with 5-aza-dC reduced the number of polyps from 113 to 
an average of 20. The combined effects of Dnmt heterozy- 
gosity and 5-aza-dC treatment resulted in only 2 intestinal 
adenomas. 
The decrease in polyp number in mice having reduced 
levels of active DNA methyttransferase was opposite to 
the result expected for a model in which global DNA hy- 
pomethylation contributes to the neoplastic process in 
colorectal cancer. The effect of DNA methyltransferase 
on Min-induced intestinal neoplasia appeared to be pre- 
dominantly on polyp number rather than size or morphol- 
ogy. The adenomas in the Dnmt ~ heterozygous mice ap- 
peared to be somewhat smaller, but this was not confirmed 
by a systematic morphometric analysis. We did not find any 
evidence for a difference in the state of differentiation r 
in the progression of the adenomas from the different ex- 
perimental groups, as assessed by histological examina- 
tion of the polyps in Min mice from all four cohorts. 
Significantly, a substantial reduction in polyp number 
was achieved in the absence of 5-aza-dC treatment. A 
slight reduction in DNA methylation levels in untreated 
Dnmt heterozygous colonic DNA is also evident in Figure 
2 (see lanes 3 and 4). Reduced DNA methylation and the 
decreased number of intestinal polyps, seen in the context 
of Apc uirv* heterozygosity, are the first examples of ob- 
served phenotypic differences between Dnmt wild-type 
mice and Dnm~ + heterozygotes. Furthermore, these re- 
sults demonstrate that Dnmt is a genetic modifier of the 
Min phenotype. It is the second such modifier to be de- 
scribed, the first being the AKR/J allele of the modifier of 
Min-1 (Mom-1; Moser et al., 1992; Dietrich et al., 1993); 
however, Dnmt and Morn-1 are distinct loci. Mom-1 maps 
to mouse chromosome 4 (Dietrich et al., 1993), whereas 
Dnmt maps to mouse chromosome 9 (Copeland et al., 
1993). 
Early Administration of 5-aza-dC Is Required for Its 
Effect on Polyp Number 
Although treatment of Min mice with 5-aza-dC had a dra- 
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Figure 4. The Number of Intestinal Polyps in Mice with Various Timed 
Treatments and Time of Sacrifice 
C57BL/6 Apc u~/+ males were crossed to either 129/Sv (circles) or 
C57BL/6 (squares) female mice. The progeny were started on weekly 
injections of 5 p~g of 5-aza-dC per 5 g of bodyweight at either 50 days 
(closed squares) or 7 days (closed circles) of age. Control mice (open 
symbols) were either injected with PBS or monitored without injection. 
In all cases, the injections were continued until the mice w re 100 
days old. The mice were sacrificed at either 100, 150, or 180 days of 
age, as indicated, and subjected to an intestinal polyp count as de- 
scribed for Figure 3. The sizes of the experimental groups were as 
follows: open squares, n = 6; closed squares, n = 9; open circles, 
n = 2, n = 5, and n = 13 for 100, 150, and 180 days, respectively; 
closed circles, n = 3, n = 2, and n = 12 for 100, 150, and 180 days, 
respectively. The treatments are indicated schematically at the bottom 
of the figure. 
matic effect on the number of intestinal polyps, the avail- 
able evidence did not provide strong indications whether 
the effect was attributable to an early influence on the rate 
of initiation of adenoma formation or, alternatively, to a 
later cytostatic or cytotoxic influence of 5-aza-dC on al- 
ready initiated adenomas. An indication that 5-aza-dC af- 
fects polyp initiation came from experiments in which drug 
treatment was delayed until day 50 in a cohort of C57BL/6 
Min mice. In this strain background, the majority of polyps 
become visible between 50 and 100 days of age (A. F., 
unpublished data; Moser et al., 1990, 1992). As can be 
seen in Figure 4, the delay in the start of 5-aza-dC treat- 
ment abolished its inhibitory effect on the number of polyps 
counted at day 100. Furthermore, there was no readily 
apparent difference in the size of polyps from mice that 
had received a delayed 5-aza-dC treatment compared with 
their PBS-treated littermates. These results suggested 
that the initiation of polyp formation occurs prior to day 
50 and is followed by a period of expansion of cell popula- 
tions in already initiated polyps in the subsequent 50 day 
period. To exert its effects on polyp number, 5-aza-dC 
must be present during this critical formative period, rather 
than during the subsequent proliferative phase. As such, 
we consider it unlikely that 5-aza-dC acts through a cyto- 
toxic or cytostatic effect on the cells in already formed 
adenomatous cell clones. 
It is also apparent from Figure 4 that the majority of 
polyps at day 180 in mice treated from day 0 to 100 ap- 
peared only after cessation of drug treatment. These ade- 
nomas may represent rapidly growing polyps initiated after 
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Figure 5. AnalysisofAIlelicLossattheApcLocusinColonAdenomas 
Intestines from randomly chosen mice from the experiment shown in 
Figure 3 were washed in PBS. Large, distinct adenomas were excised 
and processed for DNA isolation as described in Figure 2. In addition, 
normal intestinal mucosa adjacent to the polyp was excised and is 
shown immediately to the right of each polyp in the figure. The normal 
tissue in lane 9 is the control for both lanes 7 and 8. Lanes 10 and 
11 contain samples derived from tail biopsies as control DNAs. Lane 
10 is from an Apc ÷'~ mouse. Lane 11 is from an Apc =~+ mouse. PCR 
reactions were performed asdescribed in Experimental Procedures. 
The PCR products were gel-separated, blotted, and hybridized consec- 
utively with oligodeoxynucleotide probes specific for the Ape w~ allele 
(A) and for the Apc+ allele (B), and finally with a probe recognizing 
both alleles (C). 
day 100, since the experiments described above argue 
against an inhibitory effect of 5-aza-dC on the expansion 
of previously initiated polyps. This raises the possibility 
that continued treatment with 5-aza-dC could lead to the 
virtual elimination of polyp formation. 
Loss of Heterozygosity at the Apc Locus 
The precise nature of the interactions of DNA methylation 
and the mutant Apc M~" allele in tumor development were 
not made clear by these analyses. The paradigm devel- 
oped from extensive study of the Apc and similarly behav- 
ing tumor-suppressor genes dictates that loss of the wild- 
type Apc allele should accompany tumor development 
(Scrable et al., 1990; Weinberg, 1991; Boynton et al., 
1992; Ichii et al., 1992; Levine, 1993; Nakamura, 1993; 
Brewster et al., 1994; Tamura et al., 1994). We wished to 
ascertain that this genetic mechanism operated in all of 
the experimental groups studied, regardless of the status 
of their Dnmt locus or their history of 5-aza-dC treatment. 
We tested polyps from the different cohorts for loss of 
heterozygosity at the site of the Apc Mj" mutation. A seg- 
ment of DNA encompassing the mutation was amplified 
from DNA derived from polyps and from adjacent normal 
tissue. The polymerase chain reaction (PCR) products 
were hybridized consecutively with oligodeoxynucleotide 
probes specific for the Apc M~" allele and for the Apc ÷ allele, 
and finally with a probe recognizing both alleles. The rela- 
tive strengths of the signals derived from the Apc M~n- and 
Apc÷-specific probes were calculated after quantitation on 
a phosphoimager and subsequent normalization to the 
signal deriving from the probe recognizing both alleles. 
Loss of heterozygosity in polyps should reveal a reduction 
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Table 1. Analysis of Allelic Loss at the Apc Locus in Intestinal Adenomas 
Number of Polyps with Polyps with No 
Polyps Loss of Loss of 
Experimental Group Analyzed Heterozygosity Heterozygosity 
Wild-type control 12 11 1 
Heterozygote control 6 5 1 
Wild-type 5-aza-dC (0-100) 5 5 0 
Wild-type 5-aza-dC (50-100) 4 3 1 
Heterozygote 5-aza-dC (0-100) 5 4 1 
Total 32 28 4 
Intestines from randomly chosen mice from the experiment shown in Figure 1 and Figure 2 were washed in PBS. Large, distinct adenomas were 
excised and processed for DNA isolation as described previously (Laird et al., 1991). In addition, normal intestinal mucosa djacent to the polyp 
was excised as a reference standard. PCR reactions were performed as described in Experimental Procedures. The PCR products were gel- 
separated, blotted, and hybridized consecutively with oligodeoxynucleotide probes pecific for the Apc M~ allele and for the Apc* allele, and finally 
with a probe recognizing both alleles. The relative hybridization signals were quantitated with a phosphoimager. Signals were first normalized 
using the hybridization signal specific for both alleles (Apc-Uni probe). Subsequently, the ratio of Apc ~ to Apc ÷ hybridization was calculated. Most 
polyps had ratios of more than 2.0. The four polyps defined as not showing loss of heterozygosity had ratios between 0.9 and 1.1, within the range 
seen for all normal adjacent tissues. 
in the relative level of the Apc ÷ signal and an increase in 
the relative level of the Apc Mjn signal in polyps compared 
with normal adjacent tissue. 
Figure 5 shows the analysis of a representative series 
of polyps from Dnmt wild-type mice, along with control 
DNAs derived from tail biopsies from Apc Min/+ and Apc +/+ 
mice. The results obtained for all polyps analyzed are sum- 
marized in Table 1. Loss of the wild-type allele was seen 
in the majority of polyps derived from all experimental 
groups. These results are in agreement with the loss of 
heterozygosity at the APC locus seen as an early event 
in human cancer (Boynton et al., 1992; Ichii et al., 1992; 
Nakamura, 1993; Brewster et al., 1994; Tamura et al., 
1994). The high frequency of loss of heterozygosity at the 
Apc locus is close to the 100% loss of Apc heterozygosity 
in ApcMJ"-induced intestinal adenomas found by Luongo 
et al. (1994). 
We found several polyps that lacked any sign of loss of 
heterozygosity (see Figure 5 and Table 1). Such cases do 
not seem to be overrepresented in any particular cohort. 
It is possible that these polyps have lost the function of 
the wild-type allele through another mechanism, such as 
the acquisition of a mutation elsewhere in the Apc gene. 
Alternatively, loss of function of the wild-type Apc protein 
may not be an absolute requirement for polyp formation. 
In support of this, we have recently obtained evidence 
for a dominant mode of action for the truncated protein 
product of the Apc uj" allele by comparing the phenotypes 
of mice heterozygous for different Apc mutations (A. F., 
unpublished data). 
Discussion 
DNA Methyltransferase Is an Oncogenic 
Determinant in Min.lnduced Intestinal Neoplasia 
Mice carrying the Min allele of the Apc gene are predis- 
posed to intestinal polyps that become readily observable 
at several months of age (Moser et al., 1990, 1992; Luongo 
et al., 1994). As demonstrated here, the number of these 
polyps can be reduced in two ways: through treatment 
with the drug 5-aza-dC or through introduction of a mutant 
allele of the DNA methyltransferase gene. These two per- 
turbants are also united by a common biochemical mecha- 
nism of action. When incorporated into DNA, 5-aza-dC 
causes the formation of stable covalent adducts between 
DNA methyltransferase and the DNA, resulting in the 
depletion of free, active enzyme from the cell (Santi et al., 
1983, 1984; J0ttermann et al., 1994). The Dnmt smutation 
achieves the same end result through inactivation of a 
chromosomal gene copy encoding this enzyme. Indeed, 
both Dnmt heterozygosity and 5-aza-dC treatment result 
in a reduction of genomic DNA methylation levels as repre- 
sented by an analysis of centromeric repeat sequences. 
The genesis of intestinal polyps depends upon the fre- 
quency with which they are initiated and their subsequent 
ability to proliferate to a size that makes them visible under 
the dissecting microscope. Thus, the present phenomena 
need to be interpreted in light of these two events govern- 
ing observed polyp number. The initiation of polyp forma- 
tion would appear to depend upon low frequency stochas- 
tic events, in that the number of distinct clones of polyps 
is many orders of magnitude lower than the number of cells 
in the target issue. This stochastic event could involve the 
loss of the wild-type Apc allele that initially coexists with the 
mutant Apc Mr" allele in all cells of the intestinal epithelium. 
While this is an attractive idea, our results suggest that 
there are events other than the loss of Apc heterozygosity 
that can be rate-limiting for polyp formation. This is appar- 
ent from the fact that the effects of DNA methyltransferase 
levels on polyp number do not seem to be mediated 
through a change in the rate of loss of Apc heterozygosity. 
If such were the case, then we should have found a de- 
creased rate of loss of Apc heterozygosity in the mice with 
reduced numbers of polyps (Table 1). This should have 
shown up as a relative increase in the number of polyps 
without loss of Apc heterozygosity. Since this is not what 
we observed, we suggest that the effects of DNA methyl- 
transferase levels are exerted through a rate-limiting pro- 
cess other than loss of Apc heterozygosity. 
An early, rate-limiting stochastic event rather than a 
later, proliferative process would appear to be the target 
of inhibition by the 5-aza-dC that we have administered 
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to these mice. We conclude this from our observations of 
the comparative ffects of this drug administered at weekly 
intervals beginning either at the first week of life or only 
at day 50. The first protocol involving early administration 
severely depresses polyp number; in contrast, delayed 
administration has no effects on polyp number or size. 
During days 50-100 of life, these polyps undergo a size 
proliferation that causes them to become visible in the dis- 
secting microscope. Therefore, we conclude that 5-aza- 
dC has minimal effects on proliferation but profound ef- 
fects on the earlier initiation, which must occur well before 
day 50. 
Consistent with this conclusion is our recent work that 
documents the cytostatic/cytotoxic effects of 5-aza-dC 
treatment. We have found that these antiproliferative f- 
fects are not mediated through loss of DNA methylation 
per se, but rather through the formation of stable covalent 
complexes between the DNA methyltransferase nzyme 
and the incorporated cytosine analog (Santi et al., 1983, 
1984; J0ttermann et al., 1994). Consequently, cells that 
have lower levels of DNA methyltransferase are less sensi- 
tive to growth inhibition by 5-aza-dC (J0ttermann et al., 
1994). In the present study, we observed the exact oppo- 
site: the ability of 5-aza-dC to suppress polyp formation 
was stronger in mice with levels of DNA methyltransferase 
reduced owing to the Dnmt s mutation. 
DNA Methyltransferase Levels and Polyp 
Formation: Possible Mechanisms 
Studies on DNA methylation changes in human cancer 
cells have presented a somewhat confusing picture. 
Hypotheses to explain the involvement of DNA methyla- 
tion in cancer fall broadly into two classes. The first type 
proposes that changes in DNA methylation contribute to 
the oncogenic process through effects on gene expres- 
sion. The other type argues that the major role of DNA 
methylation in cancer is mediated through the dispropor- 
tionately high rate of mutation of methylated cytosine res- 
idues. 
Among the models that address gene expression-medi- 
ated effects of DNA methylation i  oncogenesis, two oppos- 
ing mechanisms have been proposed. One model proposes 
that the commonly observed global DNA hypomethylation 
in human tumors is of selective advantage to the tumor cell 
through facilitated proto-oncogene xpression (Feinberg 
and Vogelstein, 1983b; Rao et al., 1989; Vorce and Good- 
man, 1991 ; Hanada et al., 1993). In the alternative model, 
high expression of DNA methyltransferase is thought to 
drive hypermethylation of specific loci such as tumor- 
suppressor genes or genes specific to differentiated cell 
types (Kautiainen and Jones, 1986; Greger et al., 1989; 
Silverman et al., 1989; Baylin et al., 1991; EI-Deiry et al., 
1991; Issa et al., 1993, 1994; Ohtani-Fujita et al., 1993). 
This would allow outgrowth of undifferentiated neoplastic 
cells. The suppression of polyp formation by the reduction 
of DNA methyltransferase and DNA methylation levels is 
inconsistent with the first mechanism, which favors an on- 
cogenic effect of DNA hypomethylation. Our results do 
lend support for thetumor-suppressor gene hypermethyla- 
tion model, although one would have to argue that reduc- 
tion of global DNA methyltransferase l vels would affect 
local DNA hypermethylation. It is not clear how regional 
DNA hypermethylation is achieved in the face of global 
DNA hypomethylation. 
In contrast to the gene expression-mediated models 
discussed above, the mutation-mediated models propose 
that DNA methylation contributes to oncogenesis through 
a disproportionately high mutation rate of 5-methylcyto- 
sine residues (Jones et al., 1992; Spruck et al., 1993; Laird 
and Jaenisch, 1994). Deamination at cytosine-4 of both 
methylated and unmethylated cytosine residues is known 
to occur spontaneously to yield thymine and uracil, respec- 
tively (Wang et al., 1982; Ehrlich et al., 1986; Frederico 
et al., 1990; Shen et al., 1994). A uracil residue is ultimately 
substituted by thymine if it is not repaired prior to DNA 
replication. The occurrence of C to T transition mutations 
is considerably higher for 5-methylcytosine than for un- 
methylated cytosine residues. In fact, mutations of this 
sort are of significance in human tumorigenesis. Approxi- 
mately 47% of the characterized point mutations in the 
p53 tumor-suppressor gene in colorectal tumors are nucle- 
otide transitions within CpG dinucleotides, the target for 
DNA methylation (Greenblatt et al., 1994). This frequency 
contrasts with the fact that CpG dinucleotides occur within 
the coding region of the wild-type human p53 gene at a 
frequency of 3.3% (39 out of 1179). The target size for 
mutagenesis at either nucleotide within CpG dinucleotides 
is therefore 6.60. Mutations at CpG dinucleotides are thus 
overrepresented approximately 7-fold in human colorectal 
tumors (Greenblatt et al., 1994). Reduced cellular DNA 
methylation levels could lead to a lower rate of spontane- 
ous C to T transitions. If rate-limiting mutational events, 
in addition to the loss of the wild-type Apc allele, were 
required for polyp formation, then a reduced rate of C to 
T transitions could result in a lower number of intestinal 
polyps. 
The high mutation rate of methylated cytosine residues 
might also be achieved through a different mechanism 
that directly involves the DNA methyltransferase nzyme 
(reviewed in Laird and Jaenisch, 1994). The covalent en- 
zyme adduct formed between DNA methyltransferase and 
its substrate cytosine has been found to destabilize the 
amine group of the latter, resulting in an enhanced rate 
of deamination. Normally, this adduct is formed only 
ephemerally; the presence of the methyl donor S-adenosyl 
methionine (SAM) results in the rapid completion of the 
reaction and the disappearance of this destabilized inter- 
mediate. But, in the absence of sufficient amounts of SAM, 
the half-life of this intermediate may be substantially ex- 
tended, resulting, in turn, in a great increase in cytosine 
deamination. This has been demonstrated experimentally 
for a prokaryotic DNA methyltransferase (Shen et al., 
1992). If such a mechanism were also applicable to the 
mammalian enzyme, limiting levels of SAM in the intestinal 
epithelium could result in a mutagenic process with an 
activity correlating with DNA methyltransferase l vels. We 
note in passing that diets deficient in methionine have 
been reported to predispose humans to increased num- 
bers of colonic polyps (Giovannucci et al., 1993). Whether 
this is only an adventitious association or derives from a 
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mechanism associated with DNA methyltransferase-medi- 
ated deamination and mutation is not revealed by pres- 
ently available evidence. Experiments in rodents have 
shown that methyl-deficient diets, which lead to SAM 
depletion, enhance liver tumorigenesis (Mikol et al., 1983; 
Shivapurkar et al., 1986). 
Recently, the laboratories of Peter Jones and Richard 
Roberts have found evidence for yet another mechanism 
through which DNA methyltransferase nzymes could ex- 
ert an effect on cytosine mutation rates (Yang et al., per- 
sonal communication; Klimasauskas and Roberts, per- 
sonal communication). Both groups have demonstrated 
that a prokaryotic DNA methyltransferase is capable of 
high affinity binding to GU mismatches. In addition, the 
enzyme is then capable of converting the uracil residue 
to thymine by the transfer of a methyl group. GU mismatch 
repair would be inhibited directly by the binding of the DNA 
methyltransferase as well as indirectly by the conversion 
of U to T, which is less efficiently repaired in a mismatch 
with G (Shenoy et al., 1987; Brown and Brown, 1989). 
Whether the mammalian DNA methyltransferase xhibits 
similar properties remains to be seen. 
Experiments currently under way are designed to exam- 
ine the precise effects of 5-azaodC treatment and the inacti- 
vated Dnmt allele on the mutational rate of genes within 
specific tissues of the mouse. Such experiments should 
indicate whether these perturbants directly suppress mu- 
tation rate, and in turn have profound effects on the rate 
of polyp initiation in Min mice. 
Experimental Procedures 
Mice 
Mice were maintained in the facilities of the Whitehead Institute for 
Biomedical Research and were fed ad libitum. Their diet consisted of 
Agway Prolab Rat, Mouse, and Hamster 3000 chow, which has a crude 
protein content of at least 22°/0, a crude fat content of at least 5%, 
and a crude fiber content of at most 5%. C57BL/6 Apc 'a~ mice were 
purchased from the Jackson Laboratories, Bar Harbor, Maine. 129/ 
Sv Dnmt ~+ mice were generated in our facilities (Li et al., 1992, 1993). 
5-aza-dC Injections 
129/Sv Dnmt s~ female mice were crossed to C57BL/6 Apc Mi~ males. 
Progeny were weighed on a Mettler balance and injected weekly with 
either 5 p~g of 5-aza-dC per 5 g of body weight (rounded to the nearest 
multiple of 5 g) or with its solvent, PBS. The 5-aza-dC (Sigma Chemical 
Co., St. Louis, MO, catalog number A-3656) was prepared as a 2.5 
mg/ml solution in PBS and stored in aliquots at -70°C. Injections were 
performed with a 100 p.I Hamilton 700 series syringe with a Luer tip 
and a PB600 dispenser attachment, allowing injection of 50 discrete 
2 p_l volumes. The injections were started at 7 days of age and contin- 
ued for 100 days (14 injections), after which the mice were monitored 
for an additional 80 days and then sacrificed. 
Polyp Analysis 
The entire intestine~was excised immediately following sacrifice, fixed, 
and washed with Bouin's fixative and subjected to a systematic micro* 
scopic screen for polyp formation along the entire length of the intes- 
tine. Adenomas were counted if they had reached a size of at least 
two villi. The investigator counting the adenomas was blind to both 
Apc and Dnmt genotypes. Adenomas destined for DNA analysis were 
microdissected from intestines that had been washed with PBS, before 
being fixed with Bouin's fixative. 
DNA Methylation Analysis 
DNA was prepared from frozen tissue samples as described previously 
(Laird et al., 1991). Genomic DNA (5 I~g) was digested with the restric- 
tion enzyme Hpall (New England Biolabs, Beverly, MA) as specified 
by the manufacturer. After agarose gel electrophoresis followed by 
Southern blotting, the filters were hybridized with a 150 bp probe con- 
taining centromeric minor satellite repeat sequences derived from 
plasmid pMR150 (Chapman et al., 1984). 
Allellc Loss Analysis 
The murine Apc cDNA sequence was obtained from GenBank (acces- 
sion no. M88127; Suet al., 1992). A 619 bp fragment spanning the 
site of the Min mutation was amplified from genomic DNA samples 
by PCR using oligonucleotides MAPC-15 (Apc sequence 2859-2841; 
5'-TTCCACTTTGGCATAAGGC-3~ and MAPC-9 (APC sequence 
2241-2258; 5'-GCCATCCC'I-I'CACGTTAG-3'). The PCR products 
were gel-fractionated on a 2% agarosa gel, Southern blotted, and 
hybridized with three probes in sequential hybridizations. The three 
probes were Min-Sensa (Apc sequence 2542-2556; 5'-AGAAGT- 
TAGGAGAGA-3'), Apc-Sense (Apc sequence 2542-2556; 5'-AGAAG- 
TTTGGAGAGA-3'), and Apc-Uni (Apc sequence 2530-2544; 5'-TCTG- 
AGAAAGACAGA-3'). Min-Sense hybridizes specifically to the Apc '~ 
mutant allele, while Apc-Sensa hybridizes pecifically to the wild-type 
allele. Apc-Uni hybridizes to both alleles. The hybridization signals 
were quantitated using a Fuji phosphoimager. The signal levels in the 
Apc-Uni hybridization were used to normalize the amount of DNA in 
each lane. 
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Note Added in Proof 
The data referred to throughout as Yang et al., personal communica- 
tion, are now in press: Yang, A. S., Shan, J.-C., Zingg, J.-M., Mi, S., 
and Jones, P. A. (1995). Nucl. Acids Res., in press. The data referred 
to throughout as Klimasauskas and Roberts, personal communication, 
are also in press: Klimasauskas, S., and Roberts, R. J. (1995). Nucl. 
Acids. Res., in press. 
